Literature DB >> 10500855

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

I Gélinas1, L Gauthier, M McIntyre, S Gauthier.   

Abstract

OBJECTIVES: This article describes the development of an assessment of functional disability for use with proxy-respondents of community-dwelling persons who have Alzheimer's disease as well as a study testing its reliability.
METHOD: Panels composed of health care professionals and caregivers of persons with Alzheimer's disease were used to develop the Disability Assessment for Dementia (DAD). Fifty-nine caregivers participated in the refinement of the content and the testing of reliability.
RESULTS: The DAD includes 40 items: 17 related to basic self-care and 23 to instrumental activities of daily living. It demonstrated a high degree of internal consistency (Cronbach's alpha = .96) and excellent interrater (N = 31, ICC = .95) and test-retest (N = 45, ICC = .96) reliability. In addition, it was found not to have gender bias.
CONCLUSION: This instrument may help clinicians and caregivers of the population with Alzheimer's disease make decisions regarding the choice of suitable interventions.

Entities:  

Mesh:

Year:  1999        PMID: 10500855     DOI: 10.5014/ajot.53.5.471

Source DB:  PubMed          Journal:  Am J Occup Ther        ISSN: 0272-9490


  175 in total

Review 1.  Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

Authors:  Peter Johannsen
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Predictors of patient self-ratings of quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer's Disease Quality of Life Study.

Authors:  Gary Naglie; David B Hogan; Murray Krahn; B Lynn Beattie; Sandra E Black; Chris Macknight; Morris Freedman; Christopher Patterson; Michael Borrie; Howard Bergman; Anna Byszewski; David Streiner; Jane Irvine; Paul Ritvo; Janna Comrie; Matthew Kowgier; George Tomlinson
Journal:  Am J Geriatr Psychiatry       Date:  2011-10       Impact factor: 4.105

3.  Predictors of family caregiver ratings of patient quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer's Disease Quality of Life Study.

Authors:  Gary Naglie; David B Hogan; Murray Krahn; Sandra E Black; B Lynn Beattie; Christopher Patterson; Chris Macknight; Morris Freedman; Michael Borrie; Anna Byszewski; Howard Bergman; David Streiner; Jane Irvine; Paul Ritvo; Janna Comrie; Matthew Kowgier; George Tomlinson
Journal:  Am J Geriatr Psychiatry       Date:  2011-10       Impact factor: 4.105

4.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Authors:  Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Egginton; Ann M Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ulla Linnamägi; Sharon Sawchak
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

Review 5.  Withdrawal of Antidementia Drugs in Older People: Who, When and How?

Authors:  Carole Parsons
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

6.  Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.

Authors:  Onnita Thancharoen; Chulaporn Limwattananon; Onanong Waleekhachonloet; Thananan Rattanachotphanit; Phumtham Limwattananon; Panita Limpawattana
Journal:  Drugs Aging       Date:  2019-05       Impact factor: 3.923

7.  Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis.

Authors:  Dorothy Cimino Brown; Raymond C Boston; James C Coyne; John T Farrar
Journal:  Am J Vet Res       Date:  2007-06       Impact factor: 1.156

Review 8.  Clinical trial design issues in mild to moderate Alzheimer disease.

Authors:  David S Knopman
Journal:  Cogn Behav Neurol       Date:  2008-12       Impact factor: 1.600

9.  Apathy and functional disability in behavioral variant frontotemporal dementia.

Authors:  Mônica S Yassuda; Thais B Lima da Silva; Claire M O'Connor; Shailaja Mekala; Suvarna Alladi; Valeria S Bahia; Viviane Amaral-Carvalho; Henrique C Guimaraes; Paulo Caramelli; Marcio L F Balthazar; Benito Damasceno; Sonia M D Brucki; Ricardo Nitrini; John R Hodges; Olivier Piguet; Eneida Mioshi
Journal:  Neurol Clin Pract       Date:  2018-04

10.  Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.

Authors:  K Rockwood; J Mintzer; L Truyen; T Wessel; D Wilkinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.